Investor Presentaiton

China RMS Growth Drivers - - CRL China RMS Position ($) RMS China averaged robust, double-digit annual revenue growth since acquired in 2013 Recent expansion focused on R&D hubs central (Wuhan), southern (Shunde), and western (Chengdu) regions Lower, near-term growth expectations for biomedical research in China Downward trend in capital market activity in China began in 2H22 with sharper drop in 2023, which had impacted mid-tier biopharma/CRO demand Small model and services revenue in China expected to continue to grow at a faster rate than the RMS segment target over the longer term Primary drivers towards long-term goal of greater market penetration in China Continued ramp-up of capacity at new sites to assure presence in Tier 1 biohubs Synergies with and expansion of adjacent RMS service lines, including additional CRADLTM and GEMS capacity Adopt enhanced automation and digital optimization initiatives in China 37% CRL 15%+ of RMS revenue RMS China as a % of RMS segment revenue* China is CRL's largest research models region by unit volume Charles River Laboratories (CRL) * China represents only ~4% of total CRL revenue. 7

View entire presentation